Gwangju, South Korea

Jae-Il Kim

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2014

Loading Chart...
Loading Chart...
1 patent (USPTO):

Title: Jae-Il Kim: Innovator in Cancer Treatment

Introduction

Jae-Il Kim is a prominent inventor based in Gwangju, South Korea. He has made significant contributions to the field of cancer research through his innovative work on cyclin-dependent kinase inhibitors. His dedication to advancing medical science has led to the development of a unique compound with potential therapeutic applications.

Latest Patents

Jae-Il Kim holds a patent for "Indirubin-3'-oxime derivatives as potent cyclin dependent kinase inhibitors." This invention relates to an indirubin-3'-oxime derivative that exhibits strong anti-cancer activity. More specifically, it targets various human cancer cells, including lung, fibro sarcoma, colon, leukemia, stomach, nasopharyngeal, and breast cancer cells. This patent highlights his commitment to finding effective treatments for challenging diseases.

Career Highlights

Throughout his career, Jae-Il Kim has focused on the intersection of chemistry and medicine. His work has not only contributed to scientific knowledge but also holds promise for practical applications in cancer therapy. His innovative approach has garnered attention in the research community.

Collaborations

Jae-Il Kim has collaborated with notable colleagues, including Yong-Chul Kim and Soo-Ho Ban. These partnerships have facilitated the exchange of ideas and expertise, further enhancing the impact of their research.

Conclusion

Jae-Il Kim's contributions to cancer research through his innovative patent demonstrate his commitment to improving patient outcomes. His work exemplifies the potential of scientific innovation in addressing critical health challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…